Please ensure Javascript is enabled for purposes of website accessibility

FDA Warns About Unauthorized Fraudulent COVID-19 Tests

By Brian Orelli, PhD - Mar 20, 2020 at 7:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The agency hasn't approved any in-home test kits yet.

The Food and Drug Administration (FDA) is warning consumers about the marketing of unauthorized fraudulent in-home test kits designed for COVID-19, the disease caused by the new coronavirus. The FDA is worried about potential false-negative results from the kits. "They may keep some patients from seeking care or delay necessary medical treatment," the agency warned in a statement.

The FDA plans to scan ports of entry, including international mail facilities, for fake tests. It's also calling on the public to report fraudulent test kits for COVID-19 if they see them.

"We will continue to aggressively pursue those who place the public health at risk and hold bad actors accountable," the agency said.

Tube of blood marked positive for coronavirus

Image source: Getty Images.

The FDA hasn't approved any test kits for use in homes, although it's working with test-makers on taking in-home samples that can be shipped to labs to be tested. Privately held Everlywell, Nurx, and Carbon Health have all started shipping in-home sample collection kits.

The FDA has authorized tests from Abbott Labs (ABT 3.05%), Thermo Fisher Scientific (TMO 0.78%), and Roche (RHHBY 4.07%) under its Emergency Use Authorization program. The agency also gives leeway to diagnostic laboratories to develop their own tests for use in their facilities.

Despite the ramp up in authorization and production of tests, there still aren't enough tests for mass screening in the U.S., Roche's CEO Severin Schwan warned earlier this week. The lack of available tests is likely making some people desperate to get tested any way they can -- thus the FDA's warning on Friday to be on the lookout for unauthorized fraudulent test kits.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$109.45 (3.05%) $3.24
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.64 (4.07%) $1.63
Thermo Fisher Scientific Inc. Stock Quote
Thermo Fisher Scientific Inc.
TMO
$544.81 (0.78%) $4.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.